NDAORALTABLETPriority Review
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate) by Viatris (2) is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2018.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for oral treatment of HIV-1 infection. It works by inhibiting reverse transcriptase, a key enzyme in HIV replication. The combination is designed as a complete regimen for treatment-naïve and some treatment-experienced HIV patients.
$0.001BPart D
PeakDeclining
Peak lifecycle with low Part D spend ($1M) suggests mature market saturation and potential team rationalization.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYMFI currently shows zero linked job openings, indicating minimal active hiring or team expansion tied to this product. Working on SYMFI implies focus on mature brand defense and cost management rather than growth-driven innovation.
Company
Worked on SYMFI at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.